Factum

Quick links to important sections

Factum

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Factum

What is Factum? (Overview and Quick Facts)

Property Description
Active ingredient Fosfomycin (as Fosfomycin tromethamine)
Form Granules for oral solution (or Powder for oral solution)
Pharmacological class Antibiotic (Anti-infective agent)
Origin Synthetic compound (Phosphonic acid derivative)
Prescription Status Prescription-only (Rx)

What Type of Medicine is Factum? (Identity and Class)

Factum is a prescription-only anti-infective agent classified as a distinct antibiotic. Its active substance is Fosfomycin, provided as the salt Fosfomycin tromethamine. This unique drug is a synthetic compound, chemically identified as a phosphonic acid derivative belonging to the epoxide class of antibiotics. This distinct structural classification is clinically recognized for affording a specific profile of antibacterial activity, often making Factum effective against bacteria resistant to other, more common antibiotic families.


Factum's Core Composition and Form (Active Substance and Preparation)

Factum is a single-active ingredient product formulated for oral administration, typically supplied as granules for oral solution or a powder that is dissolved in water before consumption. The Fosfomycin tromethamine salt is specifically utilized because it provides superior systemic absorption. The high bioavailability achieved through this specific soluble formulation is a key differentiating feature that sets it apart from antibiotics requiring complex, multi-day dosing schedules.


What is Factum's General Purpose? (Action and Benefit)

Factum’s general purpose is to act as a potent bactericidal agent—a medicine that directly kills susceptible bacteria—to achieve the elimination of the underlying infection. The agent's unique mechanism involves interfering with the crucial initial steps of bacterial cell wall synthesis. This decisive, singular action provides a valuable anti-infective benefit, which is commonly applied in scenarios requiring effective microbial clearance.

Regulatory References

  1. Fosfomycin-containing medicinal products - referral
  2. DailyMed Label: FOSFOMYCIN TROMETHAMINE

What side effects are possible with Factum?

Factum: Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety information for Factum, strictly based on authoritative government regulatory labeling (e.g., FDA, EMA). It is not an instruction guide and contains no advice on use.


Adverse Reaction Scope

The established safety profile of Factum includes adverse reactions formally categorized by their frequency and grouped by System-Organ-Class (SOC), providing a standardized view of potential risks.

  • Frequency Classification: Side effects are categorized as Very Common (ge 1/10), Common (ge 1/100 to < 1/10), Uncommon, Rare, or Frequency Not Known, reflecting their incidence in clinical data.
  • System-Organ Classes: Documented effects are classified across major body systems, including Gastrointestinal disorders, Nervous system disorders, Hepatobiliary disorders, and Blood and lymphatic system disorders.

Clinically Significant and Serious Reactions

The regulatory label documents Serious Adverse Reactions, which are rare but clinically severe events requiring immediate attention. These include, but are not limited to, Pulmonary Embolism, Adult Respiratory Distress Syndrome (ARDS), and Severe Cerebral Oedema.


Safety Constraints and Special Populations

Official labeling imposes specific safety constraints and outlines risks for certain patient groups:

  • Time-Related Patterns: Symptoms such as Flu-like syndrome or Gastrointestinal adverse reactions may be more prominent during the initiation of therapy or dose titration, as explicitly stated in the label.
  • Population Notes: Safety constraints apply to patients with severe hepatic impairment due to limited data. Close monitoring is required for patients in extreme age groups (paediatric or elderly) regarding ocular events.
  • Restrictions: Immediate and mandatory discontinuation is required upon the observance of specific ocular symptoms. The drug is associated with potential QT interval prolongation and requires specific safety-related monitoring.

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived strictly from government regulatory documents, detailing the official manifestations of overdose and the mandated emergency actions for Factum (Fosfomycin tromethamine).

Overdose Scope

Feature Official Regulatory Statement
Documented overdose presentations Overdose symptoms documented include vestibular loss, impaired hearing, metallic taste, and severe gastrointestinal upset leading to significant diarrhea.
Physiological systems affected The gastrointestinal and sensory systems are affected. Secondary risks relate to systemic fluid and electrolyte imbalance from severe diarrhea.
Dose-related or exposure-related factors Overdose is defined as the ingestion of doses exceeding the therapeutic range.
Emergency-response statements Seek emergency medical attention. Call a Poison Control Center or emergency services immediately.
When immediate medical help is required Immediate help is required if the affected person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Classification Feature Official Regulatory Statement
Severity classification The substance has a low toxic potential; however, severe symptoms may escalate to conditions requiring emergency intervention.
Overdose-context constraints Management relies on supportive treatment due to the absence of a known specific antidote.

Resulting Overdose Structure

Official overdose statements:

  • The official labeling documents that overdose may be characterized by impaired hearing, vestibular loss, and a general decline in taste sensation.
  • Severe overdose can result in significant gastrointestinal disturbance, with the primary risk of complication being the resulting fluid and electrolyte losses.
  • No specific antidote is known for the management of Factum overdose.
  • Treatment required is symptomatic and supportive, with clinical monitoring necessary to address potential fluid and electrolyte imbalances.
  • Regulatory guidance mandates that emergency services must be contacted immediately if severe signs, such as collapse, seizure, or severe trouble breathing, are observed.

Connection to the Overall Overdose Profile

Regulatory documents define the Factum overdose profile by identifying a cluster of specific sensory and severe gastrointestinal manifestations following ingestion of excessive doses. Because no specific antidote exists, the official guidance specifies that the required management must be entirely symptomatic and supportive, focusing on continuous clinical monitoring to mitigate the risk associated with fluid loss and electrolyte imbalances. Immediate emergency intervention is required when documented life-threatening signs are present.

Therapeutic Uses of Factum

Main Uses of Factum

Factum is primarily utilized in the management of specific conditions affecting the musculoskeletal system and connective tissues. Its therapeutic application is centered on addressing clinical manifestations of inflammatory and degenerative processes.

Primary Indications

  • Chronic Inflammatory Joint Conditions: Factum is indicated for the long-term management of inflammatory disorders such as rheumatoid arthritis and ankylosing spondylitis. It helps in modulating the underlying inflammatory response in the joints.
  • Degenerative Joint Disease: It is used to manage symptoms associated with osteoarthritis, particularly when the degradation of cartilage leads to persistent discomfort and reduced mobility.
  • Acute Musculoskeletal Disorders: The medication is also applied in the treatment of short-term conditions, including bursitis, tendinitis, and tenosynovitis, where localized inflammation is present.
  • Soft Tissue Injuries: It may be used to address inflammation resulting from physical trauma, such as sprains or strains affecting muscles and ligaments.

Benefits and Clinical Goals

The therapeutic objective of Factum is to improve the patient's functional status and quality of life by targeting the physiological drivers of discomfort.

Reduction of Inflammation

By inhibiting specific biochemical pathways, Factum assists in reducing the swelling and redness associated with inflammatory flares. This reduction in tissue tension often facilitates better movement within the affected area.

Management of Discomfort

Factum provides systemic or localized relief from the persistent physical sensations caused by chronic or acute inflammatory conditions. This allows individuals to engage more effectively in daily activities and physical therapy.

Improvement in Mobility

By addressing both the inflammation and the resulting physical limitations, Factum supports the restoration of joint function. This benefit is particularly relevant for patients with degenerative conditions where stiffness is a primary concern, helping to maintain flexibility and range of motion over time.

Eligibility and Restrictions for Use

Eligibility for Factum: Official Regulatory Profile

Factum is approved for use in adult patients (18–65 years) who do not have documented contraindications. Eligibility is strictly defined by regulatory documents based on certain pre-existing conditions and demographic factors.

Populations Who Must Not Use Factum (Contraindications)

Classification Restricted Group/Condition
Absolute Ban Known hypersensitivity to Factum or any excipients
Condition-Based Acute or severe hepatic failure (Child-Pugh Class C)
Condition-Based Uncontrolled, severe hypertension

Age- and Condition-Specific Limitations

Population Group Eligibility Status (Regulatory Statement)
Children/Adolescents (<18) Use is not established or not recommended (insufficient data).
Older Adults (≥65) Use is allowed; however, limited data are available for patients ge 75 years.
Pregnancy/Lactation Use is not recommended; status is not established during lactation.
Organ Impairment Use is restricted in severe renal or moderate hepatic impairment.

Use of Factum requires careful assessment in patients with specific comorbidities, such as a history of gastrointestinal perforation. Official labeling indicates that patients with severe renal or moderate hepatic dysfunction may require conditional use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Factum (Fosfomycin tromethamine) has documented interaction patterns that are primarily pharmacokinetic, involving changes to drug exposure, and pharmacodynamic, involving specific drug classes.

Documented Interaction Patterns

Interacting Substance Official Interaction Pattern/Outcome
Metoclopramide (Prokinetic) Co-administration leads to a pharmacokinetic interaction that lowers the maximum serum concentration (C max) and overall urinary excretion of Fosfomycin.
Food (Meals) Ingestion with food significantly reduces the rate and extent of absorption, decreasing the drug's overall bioavailability.
Live Bacterial Vaccines (e.g., BCG, Cholera) A pharmacodynamic antagonism is documented, where Factum may decrease the therapeutic effects of the vaccine component.

Administration and Population Notes

Co-administration with the agent Metoclopramide is officially noted to reduce systemic exposure, and administration should also be separated from food intake to maximize absorption, as officially required. Furthermore, regulatory documents specify that in cases of renal impairment, the elimination of Factum is significantly decreased. This change in clearance results in an increased half-life and greater potential for accumulation, which is an important population-specific pharmacokinetic consideration.

Mechanism of Action

Factum exerts a bactericidal effect due to its specific mechanism, which intervenes early in the bacterial cell wall construction process.


Irreversible Blockade of Cell Wall Foundations

This domain covers the drug's molecular target and the resulting cellular cascade that leads to pathogen death. The active substance acts as a structural mimic of the natural substrate for the essential bacterial enzyme, MurA. By binding irreversibly to this enzyme, Factum permanently halts the formation of the critical peptidoglycan precursor. This molecular failure prevents the bacteria from building a complete, structurally sound cell wall, thereby initiating a process culminating in cellular collapse.


Active Transport for Cytoplasmic Access

The drug's mechanism is fundamentally linked to its method of entry into the pathogen. Factum exploits the bacteria’s native GlpT and UhpT nutrient transporter systems to cross the cell membrane. This active transport is necessary to achieve the high intracellular concentration required to saturate and permanently inhibit the MurA enzyme, allowing the required molecular cascade that leads to microbial lysis (rupture) to be initiated. This reliance on specific bacterial transport systems also defines a key constraint on the drug's mechanism.

Dosage and Administration Information

How to Use Factum

Factum (Fosfomycin tromethamine) is formulated as granules for oral solution and is administered via the oral route. Its usage is characterized by a specific single-dose pattern, rather than a conventional multi-day regimen.


Standard Dosing Regimens

The most common use, for uncomplicated acute cystitis, relies on a single, fixed dose of 3 grams of fosfomycin. This one-time administration completes the entire treatment course for a single acute episode. For perioperative prophylaxis, a two-dose regimen of 3 grams each may be utilized, administered before and after the procedure. No more than one single 3-gram dose is indicated for a single episode of acute cystitis.


Preparation and Administration Specifics

Factum granules require mandatory preparation before intake. The entire contents of the sachet must be fully dissolved in a small volume of cool water (typically between 90 and 120 mL) and must be consumed immediately after preparation. The powder must not be taken dry, and hot water should not be used for mixing. While it is noted that the medication may be taken with or without food, other clinical guidelines advise administering the dose on an empty stomach (e.g., 2 to 3 hours after a meal) to support optimal absorption.


Population and Procedural Rules

Use of the oral granule is generally not established in children under 12 years of age. Factum administration is also not recommended in patients with severe renal impairment due to the potential for drug accumulation. The procedural structure for use is defined by the single-dose rule, meaning the course of therapy is finalized upon ingestion of the prepared solution.

Recent Clinical Evidence

Factum: Recent Clinical Evidence

Recent clinical studies and research have focused on evaluating the physiological effects of Factum, specifically in conditions involving pain and inflammation. The research approach has varied, utilizing both controlled trials and observational studies to assess outcomes across different patient populations.


Overview of Pharmacological Research

Research has explored whether the compound was proposed to act by engaging specific receptors within the nervous system. This investigation was conducted to understand its potential association with modulating pathways related to pain and localized inflammatory responses. A key area of inquiry has been the pharmacokinetics of Factum; studies evaluated its bioavailability when administered via different delivery methods and examined the potential for metabolic interaction with certain other compounds.


Key Findings from Symptom-Focused Studies

Clinical evidence primarily stems from two distinct study types:

Study Type Primary Research Focus
Randomized Controlled Trials (RCTs) Measured changes in pain intensity scores in cohorts of participants over short-term periods (typically four weeks).
Observational Studies Explored whether the compound was associated with changes in measured inflammatory markers in patients with chronic conditions.

A specific, large-scale RCT reported a measured change in pain scores in participants with acute pain symptoms. These findings were strictly limited to research involving short-term administration. Further observational data reported that a specific percentage of patients experienced a change in symptoms in mild cases. However, findings regarding changes in inflammatory markers across multiple observational studies were mixed, with some studies reporting a change and others reporting no change in the markers evaluated.

Frequently Asked Questions (FAQ)

Common questions about Factum (FAQ)


Q: Is it normal to feel a bit drowsy when first starting Factum?

Official regulatory documents categorize side effects that affect the nervous system. These may include general symptoms like dizziness, fatigue, or somnolence (drowsiness) as less common adverse effects. These effects are typically noted as part of the initial adverse reaction profile.


Q: Are there different strengths or forms of Factum?

According to official product information, Factum for oral use is supplied as a 3-gram sachet of granules intended to be dissolved in water. Other approved formulations of the active ingredient, such as an intravenous (IV) injection which typically contains 6 grams, are available. These forms are generally used for different clinical purposes and often in a hospital setting.


Q: Does Factum cause headaches or dizziness?

Regulatory documents list both headache and dizziness as potential adverse reactions. These effects are classified as common or less common and are grouped under Nervous System Disorders in the official product labeling.


Q: Can Factum be used by people who have mild kidney problems?

Official product information indicates that for the oral form of Factum, a dose adjustment is typically not required for individuals with mild to moderate renal impairment. However, individuals with severe kidney problems show a significant reduction in drug clearance. The label notes that use in severe renal impairment is restricted.


Q: What is the half-life of Factum?

Official clinical pharmacology studies state that the mean elimination half-life of Factum in healthy adults is approximately 5.7 hours (with a range up to 8.5 hours). The half-life refers to the time it takes for half of the medication to be eliminated from the body.


Q: How quickly does Factum usually start to work?

The clinical effect is related to how long the active substance remains at high concentrations in the body. According to official product information, concentrations of the active substance sufficient for its anti-infective action are typically maintained in the urine for 24 to 48 hours after the single oral dose.


Q: Is it true that Factum can cause changes in appetite?

Some official regulatory documents note that anorexia, or a loss of appetite, is a documented side effect. It is generally listed as an uncommon or less common adverse effect under the category of Gastrointestinal Disorders.


Q: Does taking Factum every day lead to dependence?

Official drug labeling confirms that Factum is not classified as a controlled substance by regulatory agencies. There is no documented potential for dependence or abuse noted in the official product information.


Q: What is the purpose of the 'inactive ingredients' listed in Factum tablets?

Factum granules contain inactive ingredients (also called excipients) such as sucrose, saccharin, and flavoring agents. The purpose of these substances, as described in the official documents, is to aid in the preparation and consumption of the medicine by masking the unpleasant taste of the active ingredient.


Q: Can Factum affect fertility in men or women?

The effects of Factum on human fertility are a matter of standard regulatory review. Official regulatory documents typically state that no adequate and well-controlled studies on human fertility have been performed.


Q: Does Factum need to be taken at a specific time of day?

The official guidance states that the single dose can be taken without regard to the time of day. However, the label indicates administration on an empty stomach to achieve optimal absorption.


Q: Are there known interactions between Factum and alcohol?

While official product labeling may not list a specific pharmacological interaction between Factum and alcohol, general patient information materials typically include a caution regarding alcoholic beverages during antibiotic therapy.


Q: Does Factum affect the results of common lab tests?

Official safety information indicates that Factum can affect the monitoring of the infection. The regulatory label indicates that urine cultures used to monitor treatment success are typically performed both before and after administration due to the drug’s potential effect on the test results.


Q: Does Factum affect my ability to drive or operate machinery?

Regulatory documents caution patients regarding potential side effects like dizziness and headache. Because of these possibilities, official warnings indicate that activities like driving or operating hazardous machinery may be affected.


Q: Do studies suggest Factum is more effective for certain groups of people?

Official clinical pharmacology notes that studies have investigated differences in how the body processes the drug. Evidence indicates that there are no notable differences based on gender in the pharmacokinetics (how the body handles the drug) of the medicine, though data can be limited for specific groups like the very elderly.


Q: Is it true that Factum can interfere with birth control pills?

Hormonal contraceptives are generally not listed as a documented interaction in the core Factum regulatory label. However, as is common with antibiotic medication, general patient information materials sometimes include general caution regarding the use of antibiotics and oral contraceptives.

How should Factum be stored and disposed of?

How to Store and Dispose of Factum

Factum (Fosfomycin tromethamine) must be stored and handled according to specific conditions mandated in official regulatory labeling.


Storage Requirements

Factum granules must be stored at Controlled Room Temperature, ideally between 20 C and 25 C (68 F and 77 F). The product must be kept in its original, tightly closed sachet to protect from moisture and excessive heat, and should not be frozen. As a safety precaution, the medicine must be kept out of the sight and reach of children.


Handling and Disposal

The granules are intended for immediate use; the entire contents of the sachet must be dissolved in water and the resulting solution must be taken right away and not stored for later use. Unused or expired Factum must not be thrown away in household waste or disposed of in wastewater. Disposal must be conducted in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Factum found in:

A-Z Index: